© Momoneymoproblemz
WW International (NASDAQ:WW) has integrated its Weight Watchers Med+ offering with Eli Lilly’s (NYSE:LLY) LillyDirect healthcare platform, broadening access to its clinical weight management services for patients using or considering prescription obesity treatments.
The collaboration connects LillyDirect users with Weight Watchers’ program, which combines GLP-1 medications with behavioral, nutritional and lifestyle support.
Through the integration, patients using LillyDirect will be able to access Weight Watchers Med+, a program designed to provide medical oversight alongside structured support for long-term weight management.
LillyDirect offers patients access to independent healthcare providers, prescription fulfillment resources and educational content, while Weight Watchers Med+ adds clinical care, coaching and community-based support.
The combined approach is intended to help patients manage their treatment journey beyond simply receiving a prescription.
Weight Watchers said its Med+ platform is designed for a broad range of patients, including those evaluating weight-loss medications, individuals already taking GLP-1 therapies and people seeking ongoing support for weight management.
The program integrates care from licensed healthcare professionals with nutritional guidance, behavioral coaching and lifestyle-focused resources.
It also includes the company’s GLP-1 Success programme, which aims to help patients maximize the effectiveness of prescribed treatments while maintaining long-term health goals.
“A seamless connection from LillyDirect is central to expanding access while ensuring patients are supported beyond the prescription,” said Scott Honken, Chief Commercial Officer at Weight Watchers. “Weight Watchers Med+ is designed to support patients with the clinical and behavioral care they need to navigate weight health in real life.”
The company believes the partnership can help improve patient outcomes by pairing medication access with ongoing engagement and support.
The integration comes amid growing demand for GLP-1 weight-loss medications and increasing interest in comprehensive care models that combine pharmaceutical treatments with behavioral health services.
Weight Watchers describes itself as a science-backed weight management company and has been providing weight-related health programmes for more than six decades.
In addition to its direct-to-consumer offerings, the company also works with employers and healthcare plans through its Weight Watchers for Business platform, extending its services across a broader healthcare ecosystem.
Join the discussion: Connect with other investors on your favorite stocks or explore the top-talked-about stocks on our Breakout Boards.
This article was written by the editorial team at InvestorsHub/ADVFN and is provided for informational purposes only. In some cases, editorial staff may use artificial intelligence–based tools to assist in the research, drafting, or editing of content, under human review and oversight. This article does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. The views expressed are based on publicly available information believed to be reliable at the time of publication, but accuracy or completeness is not guaranteed. Readers should conduct their own independent research and consult a qualified financial professional before making any investment decisions.
detearing
1 year ago
airsplash2000
1 year ago
makinezmoney
1 year ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Weight Watchers Expands Reach Through LillyDirect Partnership (WW)
WW International (NASDAQ:WW) has integrated its Weight Watchers Med...